Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows provided by (used in) operating activities:
Net earnings	$ 304.6	$ 146.2	$ 719.2
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	1,039.3	712.4	375.8
Biomet merger consideration compensation expense		90.4
Intangible asset impairment	30.0
Share-based compensation	57.3	46.4	49.4
Excess income tax benefit from stock option exercises		(11.8)	(11.1)
Inventory step-up	323.3	317.8	5.4
Gain on divestiture of assets		(19.0)
Debt extinguishment	53.3	22.0
Deferred income tax provision	(153.2)	(164.0)	(90.5)
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes	(10.9)	244.7	(13.2)
Receivables	(137.8)	(56.1)	(40.4)
Inventories	76.4	(205.4)	(164.6)
Accounts payable and accrued liabilities	28.7	(252.0)	116.1
Other assets and liabilities	21.2	(21.8)	114.4
Net cash provided by operating activities	1,632.2	849.8	1,060.5
Cash flows provided by (used in) investing activities:
Additions to instruments	(345.5)	(266.4)	(197.4)
Additions to other property, plant and equipment	(184.7)	(167.7)	(144.9)
Purchases of investments	(1.5)	(214.8)	(1,350.9)
Sales of investments	286.2	802.9	1,282.2
Proceeds from divestiture of assets		69.9
Business combination investments, net of acquired cash	(421.9)		(54.3)
Investments in other assets	(3.0)	(21.7)	(4.1)
Net cash used in investing activities	(1,691.5)	(7,557.9)	(469.4)
Cash flows provided by (used in) financing activities:
Proceeds from (payments on) senior notes	1,073.5	7,628.2	(250.0)
Proceeds from term loan	750.0	3,000.0
Redemption of senior notes	(1,250.0)	(2,762.0)
Payments on term loan	(800.0)	(500.0)
Net proceeds (payments) under revolving credit facilities	(33.1)	0.1	2.3
Dividends paid to stockholders	(188.4)	(157.1)	(145.5)
Proceeds from employee stock compensation plans	136.6	105.2	284.7
Restricted stock withholdings	(6.3)	(11.1)	(7.7)
Excess income tax benefit from stock option exercises		11.8	11.1
Debt issuance costs	(10.0)	(58.4)	(64.1)
Repurchase of common stock	(415.5)	(150.0)	(400.9)
Net cash (used in) provided by financing activities	(743.2)	7,106.7	(570.1)
Effect of exchange rates on cash and cash equivalents	(22.7)	(22.6)	(18.3)
(Decrease) increase in cash and cash equivalents	(825.2)	376.0	2.7
Cash and cash equivalents, beginning of year	1,459.3	1,083.3	1,080.6
Cash and cash equivalents, end of period	634.1	1,459.3	$ 1,083.3
Biomet [Member]
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash		$ (7,760.1)
LDR Holding Corporation [Member]
Adjustments to reconcile net earnings to net cash provided by operating activities:
Biomet merger consideration compensation expense	24.1
Cash flows provided by (used in) investing activities:
Business acquisition, net of acquired cash	$ (1,021.1)